Sonoma Pharmaceuticals, Inc. (SNOA)

Market Cap	5.16M
Revenue (ttm)	12.51M
Net Income (ttm)	-5.79M
Shares Out	3.11M
EPS (ttm)	-2.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,742
Open	1.61
Previous Close	1.64
Day's Range	1.60 - 1.67
52-Week Range	1.00 - 4.25
Beta	1.04
Analysts	Buy
Price Target	n/a
Earnings Date	Feb 9, 2023

About SNOA

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing throug...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 25, 2007
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: SNOA

Financial Performance

In 2022, SNOA's revenue was $12.63 million, a decrease of -32.21% compared to the previous year's $18.63 million. Losses were -$5.09 million, 28.8% more than in 2021.